ClinicalTrials.gg
Active, not recruitingNCT06569784Updated Aug 26, 2024

Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.

A Phase 1 interventional study of [14C]HSK31858 in Healthy, sponsored by Xizang Haisco Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Xizang Haisco Pharmaceutical Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK31858 in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Xizang Haisco Pharmaceutical Co., Ltd is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese male subjects, Age: 18\~45 years old (inclusive);
  2. Body weight ≥50.0 kg and of 19 to 26 kg/m\^2(inclusive);
  3. Subjects who voluntarily signed the form, are able to communicate with the investigator and complete all study procedures as per the protocol.

Exclusion criteria

Exclusion Criteria:

Clinical examination:

  1. After physical examination, vital signs, laboratory tests (hematology, blood biochemistry, coagulation, urinalysis, stool analysis + occult blood, thyroid function), ophthalmological examination (slit lamp, intraocular pressure and fundus photography), 12-lead [Fridericia- (QTcF)-interval, which in men should be between 350-450ms (inclusive)], chest X-ray (PA and lateral), and abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidney) are abnormal and ;
  2. Subjects tested positive for surface antigen or E antigen, antibody, combined antigen/antibody (HIV-Ag/Ab), or Treponema pallidum antibody;

    Medication history:

  3. Subjects who have used prescription, over-the-counter, or healthcare drugs, including Western or proprietary Chinese medicines, within 14 days or 5 half-lives of the drug, whichever is longer, prior to screening;
  4. Subjects who have articipated in any clinical trial and received test drug or medical device intervention within 3 months prior to screening;
  5. Anyone who has used any drug that inhibits or induces activity or P-gp inhibitors within 30 days prior to screening;

    Disease history and surgical history:

  6. Prior or current history of any clinically serious disease of the cardiovascular, digestive, respiratory, endocrine, neurological, haematological, immunological, dermatological, oncological, psychiatric, and metabolic abnormalities or any other disease or physiological condition capable of interfering with the study results;
  7. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation syndrome, or a family history of the disease (as evidenced by genetic predisposition or a close relative's sudden death from cardiac causes at a young age);
  8. Subjects with a previous diagnosis of periodontitis or/and palmoplantar hyperkeratosis who are screened with the following problems:

    • Subjects with current signs of gingivitis/periodontitis;
    • Subjects with a history of hyperkeratosis of the palms or soles or erythema;
  9. Subjects who had major surgery or incompletely healed surgical incisions within 6 months prior to the screening, including, but not limited to, any surgery with significant risk of bleeding, prolonged general anaesthesia or incisional , or significant traumatic injury (with the exception of healed surgery of appendicitis or prolapse of the anus);
  10. Subjects with hyperactive immune response, including: clear sensitive to DPP1 inhibitors or any of the drug in this trial, allergy to two or more other drugs or food ingredients or special dietary requirements and inability to comply with a uniform diet;
  11. Comorbidities with haemorrhoids or perianal disease with regular/ongoing blood in stool, irritable bowel syndrome, inflammatory bowel disease;

    Lifestyle habits:

  12. Irregular bowel movements or diarrhoea;
  13. Alcohol abuse or frequent alcohol drinking within 6 months prior to screening, that is, > 14 units of alcohol consumption per week (1 unit = 360 mL beer or 45 mL of liquor with 40% alcohol or 150 mL wine), or positive result for breath alcohol test at screening;
  14. Subjects who smoke more than 5 cigarettes a day or have habitual use of nicotine containing products within 3 months prior to screening and fail to quit smoking during the trial;
  15. Subjects with a long history of drug abuse or dependence with a positive urine screen for drug abuse;
  16. Subjects with habitual consumption of grapefruit juice or excessive tea (more than 8 cups a day, 1 cup = 250mL), excessive caffeine (more than 3 cups of coffee a day, etc.) that cannot be stopped during the trial;

    Other:

  17. Subjects who engage in work requiring long-term exposure to radioactive conditions; or those with significant radioactive exposure within 1 year prior to the trial (≥ 2 chest/abdominal CT, or ≥ 3 other types of X-ray tests); or those who have participated in radiopharmaceutical studies within 1 year;
  18. Subjects with a history of fainting during acupuncture or blood phobia, difficulty in collecting blood, or inability to tolerate blood collection by venipuncture;
  19. The presence of tattoos or scars on any part of the skin that, in the judgement of the investigator, interfere with the safety assessment;
  20. Subjects having a birth plan during the trial and in 1 year after trial completion, or subjects or their spouses who refuse to take rigorous measures (including use of condoms, contraceptive sponges, contraceptive gels, contraceptive diaphragms, intrauterine devices, oral or injectable contraceptives, contraceptive implants, etc.) during the trial and in 1 year after trial completion;
  21. Subjects who had blood loss or blood donation of up to 400 mL in 3 months prior to screening, or who had received blood transfusion in 1 month prior to screening;
  22. Subjects unsuitable for participating in this trial for any other reason as judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    40 mg/120 μCi[14C]HSK31858

    \[14C\]HSK31858

    Drug: [14C]HSK31858

Interventions

  • A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.

06

What researchers measure

Primary outcomes

  1. Total radioactivity ecovery rates in urine

    Total radioactivity ecovery rates in urine at each time interval.

    Time frame: during periods of 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, 48-72 hours, 72-96 hours, 96-120 hours, 120-144 hours, 144-168 hours, 168-192 hours, 192-216 hours, 216-240 hours, 240-264 hours, 264-288 hours, and 288-312 hours post-dose

  2. Total radioactivity ecovery rates in feces

    Total radioactivity ecovery rates in feces at each time interval.

    Time frame: during periods of 0-24 hours, 24-48 hours, 48-72 hours, 72-96 hours, 96-120 hours, 120-144 hours, 144-168 hours, 168-192 hours, 192-216 hours, 216-240 hours, 240-264 hours, 264-288 hours, and 288-312 hours post-dose

  3. Cumulative total radioactivity recovery rates

    Cumulative total radioactivity recovery rates of \[14C\]HSK31858 in excretion (urine and faeces) accounting for total radiation drug dose.

    Time frame: From the start of administration to 312 hours post-dose

  4. Cmax of total radioactivity

    The pharmacokinetic parameters of total radioactivity in plasma

    Time frame: From the start of administration to 312 hours post-dose

  5. AUC(0-t) of total radioactivity

    The pharmacokinetic parameters of total radioactivity in plasm

    Time frame: From the start of administration to 312 hours post-dose

  6. AUC(0-∞) of total radioactivity

    The pharmacokinetic parameters of total radioactivity in plasm

    Time frame: From the start of administration to 312 hours post-dose

  7. %AUC

    Human plasma parent drug and its metabolites as a percentage of total plasma radioactivity exposure

    Time frame: From the start of administration to 312 hours post-dose

  8. % administered dose

    Human urine and feces parent drug and its metabolites as a percentage of administered dose

    Time frame: From the start of administration to 312 hours post-dose

  9. Identification of the main metabolites

    Identification of the main metabolites of HSK31858 in plasma, urine, and feces.

    Time frame: From the start of administration to 312 hours post-dose

Secondary outcomes

  1. AUC(0-t)

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  2. AUC(0-∞)

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  3. Cmax

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  4. Tmax

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  5. t1/2

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  6. Mean Residence Time

    The pharmacokinetic parameters of the parent drug HSK31858, metabolite M4 and other metabolites (if applicable) in plasma

    Time frame: From the start of administration to 312 hours post-dose

  7. AEs

    The incidence and severity of AEs

    Time frame: From the time of signing ICF to the end of follow-up,up to 14 days.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jul 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartActual
May 30, 2024
Primary completionActual
Jul 2, 2024
CompletionEst.
Oct 30, 2024
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06569784
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
May 30, 2024
Primary completion
Jul 2, 2024
Completion
Oct 30, 2024 (estimated)
Last update
Aug 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion